The consensus among experts was that it could be available only in a year. But a team at Oxford University hopes to have it sooner
A team from Oxford University, works on a coronavirus vaccine and could possibly be ready for public use by SeptemberThe London newspaper The Times reported.
“That is almost possible if everything goes perfectly. We have to go for it. No one can give guarantees, no one can promise that it will work and no one can give a definitive date, but we have to do everything we can as fast as we can.” said Sarah Gilbert, a professor of vaccination at the university.
The group has already developed a first version of the vaccine that will be ready to enter clinical trials in two weeks. For Gilbert, your vaccine has an 80 percent chance of success.
In statements with the British media, the scientist explained the process by which the vaccine will pass: “Firstly, there is a need to manufacture the vaccine for clinical studies under strictly controlled, certified and qualified conditions – we need ethical approval and regulatory approval. So the clinical trial can start with 500 people in phase 1. This is always in healthy adults between the ages of 18 and 55, and usually the main reading in a phase 1 study is safety. “
“Then we can do phase 2 looking at a broader age range, in this case we are going to increase the age range, from 55 to 70 years or more. We are looking for safety in the older age group, we expect to see weaker immune responses, “he explained.
How it will be tested
Gilbert clarified that the trial participants will not be intentionally infected with the virus, but will be asked to continue their lives normally, and some will presumably become infected.
“If we wait too long, a large proportion of people will be immune before we vaccinate them. So it is vital that we go fast before a high proportion becomes infected. But it also means that we are going to have to do studies in different countries because the amount of virus transmission is affected by confinement, “said Gilbert, who said his team also plans to conduct studies around the world.
“Total quarantines make it more difficult. But we also don’t want herd immunity. We want them to be susceptible and be exposed to trials just to test efficacy. It’s a matter of time, it’s not easy to predict which continents or countries will be the better places to test. “
Find out the latest on digital economy, startups, fintech, corporate innovation and blockchain. CLICK HERE